Advertisement

Picture Berlin Partner Top News Aignostics $43m AI Precision Medicine 650x100px
Document › Details

Exscientia plc. (8/28/24). "Press Release: Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference". Oxford.

Organisations Organisation Exscientia plc (Nasdaq: EXAI)
  Group Recursion Pharmaceuticals (Group)
  Organisation 2 Morgan Stanley (Group)
Products Product Morgan Stanley Global Healthcare Conference 2024 New York
  Product 2 AI-based drug discovery / AI-based drug development
Index term Index term Exscientia–Morgan Stanley: investor conference, 202409 supply service Exscientia to present at Morgan Stanley Annual Global Healthcare Conference 2024
Persons Person Hallett, David (Exscientia 202001–COO before Evotec + Merck & Co)
  Person 2 Sherman, Sara (Exscientia 202109 Investor Relations)
     


Exscientia plc (Nasdaq: EXAI) today announced that David Hallett, interim Chief Executive Officer and Chief Scientific Officer, will participate in a fireside chat at the Morgan Stanley 22 nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 7:00 a.m. EDT (12:00 p.m. BST).

A live webcast of the fireside chat will be available on the Company’s website, under the “Investors & Media” section at investors.exscientia.ai . An archived replay of the webcast will be available for approximately 30 days following the presentation.


About Exscientia

Exscientia is a technology-driven drug design and development company, committed to creating more effective medicines for patients, faster. Exscientia combines precision design with integrated experimentation, aiming to invent and develop the best possible drugs in the most efficient manner. Operating at the interfaces of human ingenuity, artificial intelligence (AI), automation and physical engineering, we pioneered the use of AI in drug discovery as the first company to progress AI-designed small molecules into a clinical setting. We have developed an internal pipeline focused on oncology, while our partnered pipeline extends to many other therapeutic areas. By leading this new approach to drug creation, we believe we can change the underlying economics of drug discovery and rapidly advance the best scientific ideas into medicines for patients.

For more information visit us on www.exscientia.com or follow us on LinkedIn @ex-scientia and X @exscientiaAI .


Investor Relations:
Sara Sherman / Chinedu Okeke
investors@exscientia.ai

Media:
David Keown
media@exscientia.ai

   
Record changed: 2024-09-11

Advertisement

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x200px

More documents for Recursion Pharmaceuticals (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x200px




» top